Advertisement

State of the Art: systemischer Lupus erythematodes

  • J. Mucke
  • R. Fischer-Betz
  • M. SchneiderEmail author
Leitthema
  • 140 Downloads

Zusammenfassung

Solange wir Erkrankungen wie den systemischen Lupus erythematodes (SLE) nicht heilen können, muss es unser Ziel sein, dass Menschen mit SLE ein weitgehend normales Leben führen dürfen. Es sollte nicht von ihrer Erkrankung dominiert werden. Ziel ist v. a. die Sekundärprävention, d. h. die Verhinderung von Schaden. Im Jahr 2020 wollen wir dafür einen besseren Beitrag leisten. Fit sein für 2020 bedeutet daher für diesen Artikel zum SLE, die Grundkonzepte der Versorgung von Patienten mit SLE regelhaft anzuwenden. Der Fokus gilt dabei v. a. den neuen Konzepten, die sich aus den neuen Klassifikationskriterien ergeben, der optimierten Grundversorgung (BASIC), der komplexen Kommunikation mit den Betroffenen, den neuen EULAR(European League Against Rheumatism)-Empfehlungen zum Monitoring von SLE, der Integration von Biologika in das Behandlungsregime, der zielgerichteten Therapie (T2T) und damit den Kriterien „low disease activity“ und Remission, der Frage nach neuen Versorgungsstrukturen für seltene und komplexe Systemerkrankungen und abschließend dem Ausblick auf zukünftige Behandlungskonzepte, deren Basis wir alle in den kommenden Jahren erschaffen werden. Wenn wir die aktuellen Möglichkeiten konsequent anwenden, können wir auch ohne neu zugelassene Medikamente die Lebenssituation und -qualität der Betroffenen weiter verbessern.

Schlüsselwörter

Treat-to-Target Remission Leitlinien Biologika Sekundärprävention 

State of the art: systemic lupus erythematosus

Abstract

As long as we cannot cure diseases such as systemic lupus erythematosus (SLE), it must be our goal that people with SLE can live a largely normal life. It should not be dominated by the disease. The main goal is secondary prevention, i. e. the prevention of harm. In 2020 we want to make a better contribution to this aim. For this article on SLE, being fit for 2020 therefore means applying the basic concepts of care for patients with SLE on a regular basis. The focus is on the new concepts resulting from the new classification criteria, the optimized basic care (BASIC), the complex communication with those affected, the new EULAR recommendations for monitoring SLE, the integration of biologics into the treatment regimen, the targeted therapy (T-2-T) and thus the criteria low disease activity and remission, the question of new care structures for rare and complex systemic diseases and finally the outlook on future treatment concepts, the basis of which we will all create in the coming years. If we consistently apply the current options, we will be able to further improve the life situation and quality of life of those affected even without newly approved drugs.

Keywords

Treat to target Remission Guidelines Biologics Secondary prevention 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

J. Mucke, R. Fischer-Betz und M. Schneider sind mit der Heinrich-Heine-Universität Düsseldorf (HHUD) affiliiert. Die Rheumatologie der HHUD wird durch nichtzweckgebundene Zuschüsse von den Firmen GlaxoSmithKline und UCB im Rahmen der Lupus-Langzeitstudie (LuLa) unterstützt.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Alexander T, Sarfert R, Klotsche J et al (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74(7):1474–1478CrossRefGoogle Scholar
  2. 2.
    Aringer M, Costenbader KH, Brinks R et al (2018) Validation of new systemic lupus erythematosus classification criteria. Ann Rheum Dis 77(Suppl):A60Google Scholar
  3. 3.
    Aringer M, Schneider M (2014) Recipes systemic lupus erythematosus. Z Rheumatol 73(6):496–500CrossRefGoogle Scholar
  4. 4.
    Aringer M, Smolen JS (2012) Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 11(5):321–325CrossRefGoogle Scholar
  5. 5.
    Bruce IN, O’Keeffe AG (2015) Farewell V et als Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 74(9):1706–1713 (Sep)CrossRefGoogle Scholar
  6. 6.
    Costedoat-Chalumeau N, Amoura Z, Hulot JS et al (2007) Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 66(6):821–824CrossRefGoogle Scholar
  7. 7.
    Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2018 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis.  https://doi.org/10.1136/annrheumdis-2019-215089 CrossRefPubMedGoogle Scholar
  8. 8.
    Franklyn K, Lau CS, Navarra SV et al (2016) Asia-Pacific Lupus Collaboration. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75:1615–1621CrossRefGoogle Scholar
  9. 9.
    Fumagalli LP, Radaelli G, al Lettieri Eet (2015) Patient Empowerment and its neighbours: clarifying the boundaries and their mutual relationships. Health Policy 119(3):384–394CrossRefGoogle Scholar
  10. 10.
    Furie R, Petri M, Zamani O, BLISS-76 Study Group (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918–3930CrossRefGoogle Scholar
  11. 11.
    Gordon C, Amissah-Arthur MB et al (2018) British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 57(1):e1–e45CrossRefGoogle Scholar
  12. 12.
    Haupt M, Millen S, Jänner M et al (2005) Improvement of coping abilities in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 64(11):1618–1623CrossRefGoogle Scholar
  13. 13.
    European Reference Network ERN ReCONNET European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases. http://reconnet.ern-net.eu. Zugegriffen: 22.04.2019
  14. 14.
    Deutsche Gesellschaft für Rheumatologie e.V. Therapieüberwachungsbögen. https://dgrh.de/Start/Versorgung/Therapieüberwachung/Therapieüberwachungsbögen.html. Zugegriffen: 22.04.2019
  15. 15.
    Humrich JY, Riemekasten G (2019) Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 31(2):208–212CrossRefGoogle Scholar
  16. 16.
    Leuchten N, Hoyer A, al Brinks Ret (2018) Systemic lupus erythematosus classification criteria steering committee. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data. Arthritis Care Res (hoboken) 70(3):428–438 (Mar)CrossRefGoogle Scholar
  17. 17.
    Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) American academy of ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394CrossRefGoogle Scholar
  18. 18.
    Merrill J, Buyon J, Furie R et al (2011) Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 20(7):709–716CrossRefGoogle Scholar
  19. 19.
    Mierau R (2016) Antinuclear antibodies without connective tissue disease : Antibodies against LEDGF/DSF70. Z Rheumatol 75(4):372–380CrossRefGoogle Scholar
  20. 20.
    Mosca M, Costenbader KH, Johnson SR et al (2019) Brief report: how do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthritis Rheumatol 71(1):91–98CrossRefGoogle Scholar
  21. 21.
    Navarra SV, Guzmán RM, Gallacher AE, BLISS-52 Study Group. et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721–731CrossRefGoogle Scholar
  22. 22.
    Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M (2005) Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64(4):630–633CrossRefGoogle Scholar
  23. 23.
    Petri M, Magder LS (2018) Comparison of remission and lupus low disease activity state in damage prevention in a united states systemic lupus erythematosus cohort. Arthritis Rheumatol 70(11):1790–1795CrossRefGoogle Scholar
  24. 24.
    Rovin BH, Furie R, Latinis K et al (2012) LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215–1226CrossRefGoogle Scholar
  25. 25.
    Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G (2014) Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology 53(8):1470–1476CrossRefGoogle Scholar
  26. 26.
    Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20–28CrossRefGoogle Scholar
  27. 27.
    Schneider M, Carnarius H, Schlegl T (2017) Shared decision making even for complex systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE)? Z Rheumatol 76(3):219–227CrossRefGoogle Scholar
  28. 28.
    Schneider M, Mosca M, Pego-Reigosa JM et al (2016) Understanding remission in real-world lupus patients across five European countries. Lupus 25(5):505–512CrossRefGoogle Scholar
  29. 29.
    Stohl W, Schwarting A, Okada M et al (2017) Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol 69(5):1016–1027CrossRefGoogle Scholar
  30. 30.
    Tektonidou MG, Ward MM (2010) Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases. Arthritis Res Ther 12(5):R179.  https://doi.org/10.1186/ar3143 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Tsang-A-Sjoe MW, Bultink IE, Heslinga M, Voskuyl AE (2017) Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology 56(1):121–128CrossRefGoogle Scholar
  32. 32.
    Ugarte-Gil MF, Wojdyla D (2017) Pons-Estel GJ et al GLADEL. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Ann Rheum Dis 76(12):2071–2074CrossRefGoogle Scholar
  33. 33.
    Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S (2019) Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis.  https://doi.org/10.1136/annrheumdis-2018-214043 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    van Vollenhoven R, Voskuyl A, Bertsias G et al (2017) A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 76:554–561CrossRefGoogle Scholar
  35. 35.
    van Vollenhoven RF, Hahn BH, Tsokos GC et al (2018) Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 392(10155):1330–1339CrossRefGoogle Scholar
  36. 36.
    van Vollenhoven RF, Mosca M, Bertsias G et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73(6):958–967CrossRefGoogle Scholar
  37. 37.
    Wallace DJ, Furie RA, Tanaka Y et al (2018) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392(10143):222–231CrossRefGoogle Scholar
  38. 38.
    Warnatz K, Goldacker S, Gause AM, Kommission Pharmakotherapie der DGRh (2013) Vaccination recommendations of the Commission for Pharmacotherapy of the German Society of Rheumatology. Z Rheumatol 72(7):687–689CrossRefGoogle Scholar
  39. 39.
    Yusuf IH, Foot B, Galloway J et al (2018) The Royal College of Ophthalmologists recommendations on .screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye.  https://doi.org/10.1038/s41433-018-0136-x CrossRefPubMedGoogle Scholar
  40. 40.
    Zen M, Iaccarino L, Gatto M et al (2015) Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 74(12):2117–2122CrossRefGoogle Scholar
  41. 41.
    Zen M, Iaccarino L, Gatto M et al (2018) Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 77(1):104–110CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Poliklinik und Funktionsbereich für Rheumatologie und Hiller Forschungszentrum, Universitätsklinikum DüsseldorfHHUDDüsseldorfDeutschland

Personalised recommendations